Jun 01, 2020
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
Feb 03, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
Nov 04, 2019
CTI BioPharma Reports Third Quarter 2019 Financial Results
Oct 01, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
Aug 01, 2019
CTI BioPharma Reports Second Quarter 2019 Financial Results
Jun 05, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
May 29, 2019
CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
Mar 13, 2019
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
Feb 01, 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Dec 28, 2018
CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
Dec 18, 2018
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
Oct 01, 2018
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
Sep 26, 2018
CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
Jul 18, 2018
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
Jul 02, 2018
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Jun 14, 2018
CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference
Jun 06, 2018
CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference
Mar 29, 2018
Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
Mar 09, 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Feb 14, 2018
CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference